Equities Analysts Issue Forecasts for Vericel Q4 Earnings

Vericel Corporation (NASDAQ:VCEL) – Research analysts at HC Wainwright lifted their Q4 2026 EPS estimates for Vericel in a research note issued on Friday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.62 per share for the quarter, up from their previous forecast of $0.50. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.73 per share. HC Wainwright also issued estimates for Vericel’s Q4 2027 earnings at $0.53 EPS.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The company had revenue of $85.37 million during the quarter, compared to the consensus estimate of $77.95 million. During the same period in the prior year, the business earned $0.10 earnings per share. The company’s revenue for the quarter was up 26.5% compared to the same quarter last year.

Several other analysts have also recently weighed in on VCEL. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. Truist Financial raised their price objective on shares of Vericel from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Stephens lifted their target price on shares of Vericel from $55.00 to $68.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, TD Cowen boosted their target price on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $62.00.

Vericel Trading Up 1.1%

Vericel stock opened at $59.03 on Monday. The stock has a 50-day moving average price of $41.74 and a two-hundred day moving average price of $39.10. Vericel has a 12 month low of $28.95 and a 12 month high of $59.72. The company has a market capitalization of $3.01 billion, a PE ratio of 91.23 and a beta of 1.08.

Insider Activity

In other Vericel news, Director Robert Zerbe sold 3,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $52.23, for a total transaction of $156,690.00. Following the transaction, the director directly owned 32,995 shares in the company, valued at approximately $1,723,328.85. This represents a 8.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jonathan Siegal sold 1,500 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $52.90, for a total transaction of $79,350.00. Following the transaction, the insider directly owned 1,259 shares in the company, valued at approximately $66,601.10. This represents a 54.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 22,000 shares of company stock valued at $1,128,340 in the last ninety days. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vericel

Several institutional investors have recently bought and sold shares of the stock. Lisanti Capital Growth LLC purchased a new position in shares of Vericel during the 2nd quarter valued at $5,356,000. Man Group plc bought a new position in shares of Vericel during the 2nd quarter worth $2,998,000. Scholtz & Company LLC bought a new position in shares of Vericel during the 2nd quarter worth $2,287,000. Bank of New York Mellon Corp bought a new position in shares of Vericel during the 2nd quarter worth $12,366,000. Finally, Madison Asset Management LLC purchased a new stake in Vericel in the 2nd quarter worth about $2,230,000.

Key Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Stephens raised its price target to $68 from $55 and maintained an “overweight” rating, implying further upside from the price cited in the report. Stephens rating information
• Positive Sentiment: HC Wainwright lifted its FY2026 EPS estimate to $0.79 from $0.45 and its FY2027 estimate to $0.89 from $0.68, also raising quarterly forecasts. It kept a “Buy” rating and a $75 price target, signaling improved earnings expectations. HC Wainwright estimate report
• Positive Sentiment: Zacks said Vericel’s earnings-estimate revisions are moving higher, a trend it viewed as supportive of further near-term share gains. Zacks earnings-estimate article
• Neutral Sentiment: A short-interest report claims a significant increase but lists short interest at zero shares and zero days to cover, making the data internally inconsistent and difficult to interpret.
• Negative Sentiment: An insider reportedly sold $778,800 worth of Vericel shares, which may raise some concern about insider sentiment, though a single sale does not establish a broader trend. Insider sale article

Vericel Company Profile

Vericel Corporation is a biopharmaceutical company focused on developing and commercializing cell therapies and other treatments for serious conditions. Based in Cambridge, Massachusetts, the company markets its products primarily in the United States. Its products include MACI, an implant made from a patient’s own cultured cartilage cells used to repair certain cartilage defects in the knee, and Epicel, a cultured skin graft used to treat patients with deep burns. Vericel also commercializes NexoBrid in the United States, an enzyme-based treatment for removing dead tissue from severe thermal burns.